Our Alumni, Frequency Therapeutics, Announces $32 Million Series A Investment. Congratulations!
Congratulations to our alumni, Frequency Therapeutics team with this great achievement!
The funding of $32 million Series A will support their clinical development and research for hearing restoration therapeutic. We wish you all the best in your future endeavors.
Frequency Therapeutics,a company developing a pipeline of new drugs that activate progenitor cells within the body, today announced the closing of a $32 million Series A financing. The funding round was led by CoBro Ventures. Additional participating investors included Morningside Ventures, Emigrant Capital Corp., Korean Investment Partnership, Alexandria Real Estate Equities and other U.S. and international investors.
Read more here.